Checkpoint blockade in esophagogastric cancer

Cohen, Noah A.; Strong, Vivian E.; Janjigian, Yelena Y.

doi:10.1002/jso.25116

Cited by 10 publications

(12 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, immune checkpoint blockade has been focused as a promising molecular targeted immune therapy in patients with various malignancies, including gastric cancer [5,6]. The ATTRACTION-2 trial of nivolumab, an anti-programmed cell death protein 1 (PD-1) antibody, in patients previously treated with advanced gastric or gastroesophageal junction cancer, found 1-year overall survival (OS) rates of 27.3 and 11.6% in the nivolumab and placebo groups, respectively [7,8].…”

Section: Introductionmentioning

confidence: 99%

Response Rate and Prognostic Impact of Salvage Chemotherapy after Nivolumab in Patients with Advanced Gastric Cancer

et al. 2020

View full text Add to dashboard Cite

Objective: Nivolumab is recommended as a third-line treatment in patients with unresectable advanced or recurrent gastric cancer. Although recent studies have demonstrated the prognostic impact of salvage chemotherapy after immune checkpoint inhibitors in several malignancies, its clinical significance remains unclear in patients with gastric cancer. This study aimed to investigate tumor response to subsequent chemotherapy after nivolumab in patients with advanced gastric cancer and assess the prognostic effect of salvage chemotherapy. Methods: We retrospectively enrolled 31 patients with unresectable advanced or recurrent gastric cancer receiving nivolumab. Results: Twenty-two and nine patients received nivolumab as third-line and fourth-to sixth-line treatments, respectively. The objective response rate (ORR) and disease control rate (DCR) to nivolumab were 20.0% (4/20) and 55.0% (11/20), respectively. Eleven patients received salvage chemotherapy after nivolumab. The ORR and DCR to salvage chemotherapy were 37.5% (3/8) and 75.0% (6/8), respectively. The median progression-free survival and overall survival following salvage chemotherapy were 285 and 360 days, respectively. Conclusion: Our preliminary study indicates that nivolumab exposure may enhance subsequent chemosensitivity in patients with advanced gastric cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Response Rate and Prognostic Impact of Salvage Chemotherapy after Nivolumab in Patients with Advanced Gastric Cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In Brazil, an estimated 11390 new cases, corresponding to 8690 in men and 2077 in women for the year 2020 [4]. About half of the people with cancer of the esophagus or the gastroesophageal junction have metastatic disease at diagnosis, and there are few effective options after the progression of second-line chemotherapy [5,6]. Thus, surgery with or without adjuvant or neoadjuvant therapy is the treatment of choice for resectable cases with curative intent [7].…”

Section: Introductionmentioning

confidence: 99%

“…Immune checkpoint blocking is a promising treatment strategy for certain cases of advanced cancer, and the immunotherapy strategies that had been used in patients with melanoma, non-small cell lung cancer and urothelial cancer were tested in patients with AJEG [9]. As a result, Pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor, has recently been approved for metastatic or recurrent JEG that has progressed beyond the second line of systemic therapy and has been used effectively in the present case report [6]. Therefore, it is necessary to find new options for these patients due to high mortality in view of the limitations of first-line treatments.…”

mentioning

confidence: 99%

Durable and Effectiveness of Immunotherapy in the Treatment of Metastatic Gastroesophageal Junction Cancer

Moreira¹,

Bittencourt²,

Nogueira³

et al. 2020

Int J Immunol Immunother

View full text Add to dashboard Cite

“…Speci cally, the recent advancement of chemotherapy led to signi cant prognostic improvements in patients with unresectable advanced or recurrent gastric cancer [1]. Some studies focused on immunotherapy as a novel promising tool in patients with various malignancies, including gastric cancer [2][3][4][5]. Nivolumab, an antiprogrammed cell death protein 1 antibody, is one of the representative immune checkpoint inhibitors.…”

Section: Introductionmentioning

confidence: 99%

Recurrent gastric cancer sustaining a partial response after the nivolumab discontinuation because of immune-related adverse events: a case report

Arigami

Matsushita

Okubo

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The prognosis of patients with recurrent gastric cancer is extremely poor despite chemotherapy being clinically recommended as the first therapeutic strategy. Recent clinical trials have established the clinical utility of nivolumab in the third-line treatment of such patients. Remarkably, immune-related adverse events (irAE) have been focused as a promising predictor for tumor response to nivolumab. This report aims to present a long-term survivor of recurrent gastric cancer who was followed up without any treatments after the nivolumab discontinuation because of irAE.Case presentation: A 65-year-old male with stage III gastric cancer (cT4aN1M0) underwent distal gastrectomy and a partial resection of the transverse colon with D2 lymph node dissection after neoadjuvant chemotherapy. Owing to the final pathological stage IIIB (ypT4bN1M0), the patient received adjuvant chemotherapy. Nevertheless, during adjuvant chemotherapy 1-year post-surgery, computed tomography (CT) revealed lymph node swelling in station no. 9. Thus, upon diagnosis with lymph node recurrence, the patient was treated with two courses of capecitabine + oxaliplatin and three courses of ramucirumab + paclitaxel as the first- and second-line regimens, respectively. Based on these regimens, the patient had a progressive disease to chemotherapy. Consequently, we administered nivolumab 3 mg/kg intravenously every 2 weeks and 240 mg/kg intravenously every 2 weeks after September 2018 as the third-line regimen. After four courses of nivolumab, CT revealed a significant shrinkage of the metastatic lymph node, with a 45.6% reduction. We confirmed a partial response during 11 courses of nivolumab. Since the occurrence of grade 4 diabetes mellitus after 12 courses of nivolumab, the patient was followed up without any treatment after the nivolumab discontinuation. Currently, the patient remains a partial response for 15 months since the nivolumab discontinuation and is alive for 31 months after disease recurrence.Conclusions: Acute irAE during nivolumab chemotherapy could be one of the crucial clinical factors to predict tumor suppression in patients with advanced gastric cancer.

show abstract

Checkpoint blockade in esophagogastric cancer

Cited by 10 publications

References 53 publications

Response Rate and Prognostic Impact of Salvage Chemotherapy after Nivolumab in Patients with Advanced Gastric Cancer

Response Rate and Prognostic Impact of Salvage Chemotherapy after Nivolumab in Patients with Advanced Gastric Cancer

Durable and Effectiveness of Immunotherapy in the Treatment of Metastatic Gastroesophageal Junction Cancer

Recurrent gastric cancer sustaining a partial response after the nivolumab discontinuation because of immune-related adverse events: a case report

Contact Info

Product

Resources

About